Exploring novel vaccines against Helicobacter pylori: protective and therapeutic immunization.
Infection of human stomach by Helicobacter pylori, a gram negative spiral bacterium first isolated in 1983 from a patient with chronic active gastritis (1), causes nearly all duodenal ulcers and most gastric ulcers and is associated with an increased risk of gastric adenocarcinoma (2). Current thera...
| Publicado en: | Journal of Clinical Pharmacy & Therapeutics Vol. 24; no. 4; pp. 259 - 273 |
|---|---|
| Autores principales: | , |
| Formato: | research Journal Article |
| Publicado: |
Wiley-Blackwell
Aug99
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105975063&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 105975063 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 02694727 EV4 jtl: Journal of Clinical Pharmacy & Therapeutics issn: 02694727 maglogo: Y pubinfo: dt: Aug99 vid: 24 iid: 4 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 105975063 2009783215 10.1046/j.1365-2710.1999.00226.x NLM10475984 105975063 ppf: 259 ppct: 14 formats: fmt: @attributes: type: P tig: atl: Exploring novel vaccines against Helicobacter pylori: protective and therapeutic immunization. aug: au: Vyas SP Sihorkar V sug: subj: Bacterial Vaccines Therapeutic Use Helicobacter Infections Prevention and Control Helicobacter Pylori Immunology Stomach Diseases Prevention and Control Animals Bacterial Vaccines Economics Drug Resistance, Microbial Physiology Forecasting Helicobacter Infections Epidemiology Immunization Economics Peptic Ulcer Complications Peptic Ulcer Prevention and Control Research Stomach Neoplasms Etiology Animal Studies ab: Infection of human stomach by Helicobacter pylori, a gram negative spiral bacterium first isolated in 1983 from a patient with chronic active gastritis (1), causes nearly all duodenal ulcers and most gastric ulcers and is associated with an increased risk of gastric adenocarcinoma (2). Current therapies for gastric infections include combination triple or quadruple therapy of antimicrobial and/or antiulcer agents for eradication of H. pylori infection (3). Development of the resistant strains and ecological niche (habitant) of the bacteria may cause relapse after the termination of the therapy. However, if effective, the high cost, difficulty of patient compliance and risk of selection for resistant strains make these therapeutic regimens impractical on a large scale, though effective on the laboratory trial stages. Studies of the pathogenesis of H. pylori have led to the identification of bacterial antigens and adherin proteins as candidates for inclusion as novel vaccines against these diseases (4-7). Both prophylactic and therapeutic vaccination have been demonstrated in animal models of H. pylori infection (8-10). pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|